Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics 2014. CA Cancer J Clin, 2014; 64: 252-71.10.3322/caac.2123524890451Search in Google Scholar

2. American Cancer Society. Cancer Facts & Figures 2014. Atlanta, GA: American Cancer Society; 2014.Search in Google Scholar

3. National Cancer Institute. Small cell lung cancer treatment. [citated 2015 Jan 15]. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional/page1/AllPages#Section_267. 2014.Search in Google Scholar

4. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al.: A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618-24.10.1056/NEJM1992120332723021331787Search in Google Scholar

5. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10: 890-5.10.1200/JCO.1992.10.6.8901316951Search in Google Scholar

6. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17: 658-67.10.1200/JCO.1999.17.2.65810080612Search in Google Scholar

7. O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-7.10.1200/JCO.2006.06.582117135646Search in Google Scholar

8. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007; 25: 2086-92.10.1200/JCO.2006.08.399817513814Search in Google Scholar

9. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-9.10.1093/jnci/djp369413723219903805Search in Google Scholar

10. Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 2010; 21: 2324-32.Search in Google Scholar

11. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.10.1200/JCO.2007.14.546619188680Search in Google Scholar

12. Hotta K, Kiura K, Fujiwara Y, Takigawa N, Hisamoto A, Ichihara E, et al. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review. PloS one 2011; 6: e26646.10.1371/journal.pone.0026646321963322114662Search in Google Scholar

13. Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 1537-41.10.1093/annonc/mdr48722039091Search in Google Scholar

14. Imai H, Mori K, Wakuda K, Ono A, Akamatsu H, Shukuya T, et al. Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. Ann Thorac Med 2015; 10: 61-6.Search in Google Scholar

15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.10.1093/jnci/92.3.205Search in Google Scholar

16. Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988; 6: 1264-70.10.1200/JCO.1988.6.8.1264Search in Google Scholar

17. Ebi N, Kubota K, Nishiwaki Y, Hojo F, Matsumoto T, Kakinuma R, et al. Second-line chemotherapy for relapsed small cell lung cancer. Jpn J Clin Oncol 1997; 27: 166-9.10.1093/jjco/27.3.166Search in Google Scholar

18. Johnson KR, Ringland C, Stokes BJ, Anthony DM, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006; 7: 741-6.10.1016/S1470-2045(06)70800-2Search in Google Scholar

19. Hotta K, Fujiwara Y, Matsuo K, Kiura K, Takigawa N, Tabata M, et al. Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer. J Thorac Oncol 2009; 4: 311-7.10.1097/JTO.0b013e3181989bd219190515Search in Google Scholar

20. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011; 117: 1262-71.10.1002/cncr.25526302526720960500Search in Google Scholar

21. Hayashi H, Okamoto I, Taguri M, Morita S, Nakagawa K. Post progression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. Clin Lung Cancer 2013; 14: 261-6.10.1016/j.cllc.2012.09.00623107465Search in Google Scholar

22. Imai H, Takahashi T, Mori K, Ono A, Akamatsu H, Shukuya T, et al. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer. Neoplasma 2014; 61: 233-40.10.4149/neo_2014_03024299320Search in Google Scholar